Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02802943
Recruitment Status : Recruiting
First Posted : June 16, 2016
Last Update Posted : September 17, 2019
Robert Bosch Gesellschaft für Medizinische Forschung mbH
Klinikum Stuttgart
Marienhospital Stuttgart
Katharinenhospital Stuttgart
Information provided by (Responsible Party):
University Hospital Tuebingen

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2020
Estimated Study Completion Date : December 31, 2020